Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations

Abstract

Objective To assess the prognostic value of clinicopathological factors as well as BRAF and TERT promoter mutations in predicting distant metastasis in patients with papillary thyroid cancer.

Design The status of BRAF and TERTp mutations were available in 1,208 thyroid cancer patients who received thyroidectomy at Jiangyuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine from January 2008 to December 2021. Based on inclusion criteria, 99 distant metastasis thyroid cancers (DM-TCs) and 1055 patients without DM (Non-DM-TCs) were retrospectively reviewed.

Results After univariate and multivariate analyses, a risk model was established for DM prediction based on factors: T3/T4 stage, lymph node metastasis (LNM) number over 5, and BRAF/TERT mutations (TLBT). It was defined based on the number of TLBT factors: low risk (no risk factor, n=896), intermediate risk (1 risk factor, n=199), and high risk (≥2 risk factors, n=59). Notably, compared with patients with low and intermediate risks, patients assigned to high TLBT risk have a shorter time of DM disease-free survival. Except for gene mutation, other factors were also included in the 2015 American Thyroid Association (ATA) risk guideline. Comparing with the ATA risk category, this risk model showed a better performance in predicting DM-TCs.

Conclusions This study proposes a TLBT risk classifier consisting of T3/T4 stages, LNM (n>5), and BRAF+TERTp mutations for predicting DM-TCs. TLBT risk stratification may help clinicians make personalized treatment management and follow-up strategies.

Key words

papillary thyroid cancer - distant metastasis - T stage - lymph node metastasis - BRAF/TERTp mutations

• References

• 1 Haugen BR, Alexander EK, Bible KC. et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133
• 2 Bartel Chair TB, Magerefteh S, Avram AM. et al. SNMMI procedure standard for scintigraphy for differentiated thyroid cancer. J Nucl Med Technol 2020; 48: 202-209
• 3 Huang X, Xia Q, Huang Y. et al. Age increased the cancer-specific mortality risk of thyroid cancer with lung metastasis. Clin Endocrinol (Oxf) 2022; 96: 719-727
• 4 Siraj AK, Parvathareddy SK, Annaiyappanaidu P. et al. Male sex is an independent predictor of recurrence-free survival in middle eastern papillary thyroid carcinoma. Front Endocrinol (Lausanne) 2022; 13: 777345
• 5 Liu W, Wang S, Ye Z. et al. Prediction of lung metastases in thyroid cancer using machine learning based on SEER database. Cancer Med 2022; 11: 2503-2515
• 6 Parvathareddy SK, Siraj AK, Qadri Z. et al. Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma. Endocr Connect 2022; 11: e210518
• 7 Wijewardene A, Gill AJ, Gild M. et al. A retrospective cohort study with validation of predictors of differentiated thyroid cancer outcomes. Thyroid 2022; 32: 1201-1210
• 8 Bonhomme B, Godbert Y, Perot G. et al. Molecular pathology of anaplastic thyroid carcinomas: A retrospective study of 144 cases. Thyroid 2017; 27: 682-692
• 9 Bullock M, Ren Y, O’Neill C. et al. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin Endocrinol (Oxf) 2016; 85: 283-290
• 10 Cao J, Zhu X, Sun Y. et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Eur J Nucl Med Mol Imaging 2022; 49: 3470-3481
• 11 Simões-Pereira J, Mourinho N, Ferreira TC. et al. Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer. J Clin Endocrinol Metab 2021; 106: e3911-e3922
• 12 Park J, Lee S, Park J. et al. Proposal of a new prognostic model for differentiated thyroid cancer with TERT promoter mutations. Cancers (Basel) 2021; 13: 2943
• 13 Park H, Shin HC, Yang H. et al. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol 2022; 35: 186-192
• 14 Ito Y, Akamizu T. TERT promoter mutation as a prognostic marker in encapsulated angioinvasive and widely invasive follicular thyroid carcinomas. Clin Thyroidol 2023; 35: 202-204
• 15 Ho AS, Luu M, Shafqat I. et al. Predictive impact of metastatic lymph node burden on distant metastasis across papillary thyroid cancer variants. Thyroid 2021; 31: 1549-1557
• 16 Leite AK, Saito KC, Theodoro TR. et al. Profile of microRNAs associated with death due to disease progression in metastatic papillary thyroid carcinoma patients. Cancers (Basel) 2023; 15: 869
• 17 Gubbiotti MA, Livolsi V. Brain metastases of papillary thyroid carcinoma origin are derived from aggressive histologic variants and demonstrate similar adverse morphology in the metastatic lesion. Clin Neurol Neurosurg 2023; 227: 107639
• 18 Tong J, Jiang W, Zhang X. et al. CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma. J Int Med Res 2022; 50: 3000605221139555
• 19 González-Clavijo AM, Cuellar AA, Triana-Urrego J. et al. Metastatic differentiated thyroid cancer: Worst prognosis in patients with metachronous metastases. Endocrine 2023; 81: 90-97